Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
Study Details
Study Description
Brief Summary
This is a Phase 1, Open-Label, Dose Escalation and Expansion, Multicenter Study of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects with Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
This is a Phase 1, open label, multicenter study to evaluate Claudin 18.2-targeting CAR-T cells (LB1908) in adult subjects with unresectable, locally advanced or metastatic gastric, GEJ, esophageal, or pancreatic adenocarcinoma. Patients will be confirmed to have sufficient expression of Claudin 18.2 as part of a prescreening. The study comprises a dose-escalation component (Part A) and a dose-expansion component (Part B). In part A, patients with gastric, GEJ, or esophageal adenocarcinoma will be treated with LB1908 at protocol-defined dose level, with escalation to higher doses in subsequent patients guided by evaluation of protocol-defined dose limiting toxicities (DLTs). Part A will identify the recommended dose for expansion (RDE) to be tested in part B in two cohorts: a gastric, GEJ and esophageal adenocarcinoma cohort as well as a pancreatic adenocarcinoma cohort. Part B will aim to identify the recommended dose for phase 2 (RP2D).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Experimental LB1908 Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells |
Biological: LB1908
Claudin 18.2-Targeted autologous Chimeric Antigen Receptor T-cells
|
Outcome Measures
Primary Outcome Measures
- To characterize the safety and tolerability of LB1908 and determine the optimal dose or recommended dose for expansion (RDE) [28 days]
Multiple doses will be tested to establish a recommended dose.
- To further characterize the safety and tolerability of LB1908 with the RDE identified in the dose-escalation and determine the recommended Phase 2 dose (RP2D) [90 days]
Treatment of additional patients at the recommended dose as identified in the initial dose escalation part of the study.
Secondary Outcome Measures
- To evaluate the preliminary efficacy of LB1908 [Through study completion, a minimum of 2 years]
Measured by Response Evaluation Criteria In Solid Tumors (RECIST)
- To characterize the pharmacokinetics of LB1908 in blood [Through study completion, a minimum of 2 years]
CAR-positive T cell counts, CAR transgene level in blood
- To evaluate the immunogenicity of LB1908 [Through study completion, a minimum of 2 years]
Presence of anti-LB1908 antibodies
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Be willing and able to provide written informed consent
-
Be a female or male ≥ 18 and ≤ 75 years old at the time of signing of the informed consent
-
For Part A and B: subjects with histologically/cytologically confirmed unresectable, locally advanced or metastatic adenocarcinoma of the stomach, GEJ, or distal esophagus for which standard treatment is considered intolerable, unlikely to confer significant clinical benefit, is no longer effective, does not exist, or subject is ineligible or declines standard therapy.
For Part B only: subjects with histologically/cytological confirmed unresectable, locally advanced or metastatic adenocarcinoma of the pancreas for which standard treatment is considered intolerable, unlikely to confer significant clinical benefit, is no longer effective, does not exist, or subject is ineligible or declines standard therapy.
- Subjects must have received prior therapy as follows:
-
For gastric, GEJ, or esophageal adenocarcinoma, previous treatment must have included a fluoropyrimidine and/or platinum containing regimen. Subjects with HER2-neu-positive (HER2+) disease must have also received prior anti-HER2+ therapy.
-
For pancreatic adenocarcinoma, previous treatment must have included fluoropyrimidine and/or gemcitabine containing regimen.
-
Presence of CLDN18.2 positive tumors with staining intensity of ≥ 1+ in ≥ 50% of tumor cells by immunohistochemistry (performed by central laboratory during Prescreening)
-
Presence of ≥ 1 radiologically measurable lesion per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1.
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
-
Life expectancy of at least 4 months per investigator judgment.
-
Have adequate organ function
-
Women of childbearing potential must have a negative pregnancy test at screening
-
All Subject must agree to practice a highly effective method of contraception from the time of signing the ICF to 1 year after receiving a LB1908 infusion.
-
Women and men must agree not to donate eggs (ova, oocytes) or sperm, respectively, until at least 1 year after receiving a LB1908 infusion.
Exclusion Criteria:
-
Prior treatment with cellular immunotherapy (e.g., CAR-T) or gene therapy product.
-
Prior treatment with claudin 18.2-targeted therapy.
-
Antitumor therapy prior to apheresis during the protocol-defined window
-
Subjects who have a history of esophageal or gastric resection that the investigator considers is at increased risk of bleeding or perforation;
-
Unstable/active ulcer, varices, or digestive tract bleeding or recent digestive surgery that may have increased risk of bleeding;
-
Clinically significant ascites, pleural or peritoneal effusions requiring weekly clinical intervention at screening.
-
Patients requiring anticoagulant therapy such as warfarin or heparin
-
Patients requiring long-term antiplatelet therapy
-
Primary immunodeficiency
-
Known brain metastasis or leptomeningeal metastasis.
-
Subjects with heavy tumor burden such as significant lung disease or extensive liver metastases.
-
Active autoimmune disease receiving immunosuppressants (e.g., cyclosporine or high dose systemic steroids) within 2 weeks or 5 half-lives prior to screening
-
Impaired cardiac function or clinically significant cardiac disease as defined by the protocol
-
Previous or concurrent malignancy not meeting protocol-defined exceptions
-
Serious and /or uncontrolled medical condition that, in the Investigator's judgment, would cause unacceptable safety risk, interfere with study procedures or results, or compromise compliance with the protocol:
-
Current known active infection with human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C virus (HBV/HCV).
-
Contraindications or life-threatening allergies, hypersensitivity, or intolerance to LB1908 excipients, such as dimethyl sulfoxide; or to fludarabine, cyclophosphamide, or tocilizumab.
-
Ongoing toxicity from previous anticancer therapy that has not resolved to Grade 2 or less, except for alopecia, fatigue, nausea, and constipation.
-
Major surgery within 4 weeks prior to apheresis, or planned within 4 weeks after LB1908 administration.
-
Pregnant or breast-feeding.
-
Plans to become pregnant or breastfeed, or father a child within 1 year after receiving a LB1908 infusion.
-
Previous history of allogeneic HSCT, organ transplant, or in preparation for organ transplant.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Legend Biotech USA Inc
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- LB1908-1001